The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final results of a multicenter phase II trial assessing sorafenib (S) in combination with irinotecan (i) as second- or later-line treatment in metastatic colorectal cancer (mCRC) patients (pts) with KRAS-mutated tumors (mt; NEXIRI).
M. Ychou
Consultant or Advisory Role - Bayer
Research Funding - Bayer
O. Bouche
Consultant or Advisory Role - Pfizer
Honoraria - Bayer
S. Thézenas
No relevant relationships to disclose
E. Francois
Consultant or Advisory Role - Merck Serono; Pfizer; Roche
Honoraria - Merck Serono; Roche
Research Funding - Merck Serono; Roche
A. Adenis
No relevant relationships to disclose
J. Bennouna
No relevant relationships to disclose
J. Taïeb
No relevant relationships to disclose
F. Desseigne
No relevant relationships to disclose
J. Seitz
Consultant or Advisory Role - Bayer
T. Conroy
No relevant relationships to disclose
M. Galais
No relevant relationships to disclose
E. Crapez
No relevant relationships to disclose
S. Poujol
No relevant relationships to disclose
F. Bibeau
No relevant relationships to disclose
P. Laurent-Puig
No relevant relationships to disclose
E. Samalin
No relevant relationships to disclose